Top Tweets for #mpns
Anemia remains one of the toughest challenges in myelofibrosis management. Anthony M. Hunter, MD, breaks down where luspatercept fits among other treatment options and how he approaches the decision for individual patients.
See more: https://t.co/wjEX2RCFoL
#Myelofibrosis #MPNs #Luspatercept
โฐ In #MPNs, timing may matter as much as the mutation.
Data suggest patients who acquire TP53 mutations later in their disease course face worse survival outcomes than those with earlier acquisition.
๐น Akriti G. Jain, MD of @CleClinicMD | #ASCO26
https://t.co/yBEEOQhTil
โญ EXCLUSIVE: Get a sneak peek of what's to come at #EHA2026 this week in our new curated preview, including advances in #CLL, #myeloma, #MPNs, and more.
๐ฉธ Find the preview here (free sign-up required): https://t.co/LhqNmXvYDU
#EHA26 #Hematology #Oncology #BloodCancer
Research linking #MPNs, treatment, and skin cancer risk is helping doctors improve screening and prevention.
Support the science protecting patients today and improving care tomorrow.
๐Invest in research: https://t.co/lFQHTXf2Nc
#BloodCancer #SkinCancerAwareness
The FDA has approved ruxolitinib extendedโrelease (Jakafi XRโข), a onceโdaily tablet for adults with #myelofibrosis and #polycythemiavera. Ongoing research helps clarify how new formulations may fit into MPN care. #MPNs #MPNresearch
While bone marrow biopsies are currently used to diagnose primary and secondary #myelofibrosis (MF), new research indicates that circulating CD34-positive cells with a threshold of 10/ยตL at diagnosis can distinguish primary MF from other #MPNs: https://t.co/np54KvUWdd
5/
Overall our study suggests HOHF is not uncommon in MF and is a possible marker for advanced disease. This is more evidence that #echofirst may be useful in identifying high risk patients in #MPNs
@GabyHobbs @datsunian @HJRyooAli @doctorpemm @myeloidmalig @Anand_88_Patel
Missed our Post-ASH #MPNs webinar? ๐ค Explore the highlights now, including panel discussions where your questions get answered! ๐ฉธ ๐ฅ
Featuring presentations & discussions on selected #MPN abstracts from the 67th ASH Annual Meeting and Exposition ๐ก
Covering:
๐น Session 1: Advances in the management of PV and ET
๐น Session 2: Latest in MF therapies
๐น Session 3: Novel therapeutic approaches for MPNs and #mastocytosis
Chair: @harrisoncn1
Moderators: Francesca Palandri and John Mascarenhas
Give it a watch ๐ https://t.co/lp8fQ0gLd2
#HemOnc
Missed our Post-ASH #MPNs webinar? ๐ค Explore the highlights now, including panel discussions where your questions get answered! ๐ฉธ ๐ฅ
Featuring presentations & discussions on selected #MPN abstracts from the 67th ASH Annual Meeting and Exposition ๐ก
Covering:
๐น Session 1: Advances in the management of PV and ET
๐น Session 2: Latest in MF therapies
๐น Session 3: Novel therapeutic approaches for MPNs and #mastocytosis
Chair: @harrisoncn1
Moderators: Francesca Palandri and John Mascarenhas
Give it a watch ๐ https://t.co/lp8fQ0gLd2
#HemOnc
Congrats to Dr. Ann Mullally and colleagues on a new study clarifying risk in TP53-mutated #MPNs. By defining key factors that shape disease course, this work supports more informed monitoring.
Learn more here: https://t.co/7ZfB2xSveo
ย #MPNresearch #bloodcancer
Missed our Post-ASH #MPNs webinar? ๐ค Explore the highlights now, including panel discussions where your questions get answered! ๐ฉธ ๐ฅ
Featuring presentations & discussions on selected #MPN abstracts from the 67th ASH Annual Meeting and Exposition ๐ก
Covering:
๐น Session 1: Advances in the management of PV and ET
๐น Session 2: Latest in MF therapies
๐น Session 3: Novel therapeutic approaches for MPNs and #mastocytosis
Chair: @harrisoncn1
Moderators: Francesca Palandri and John Mascarenhas
Give it a watch ๐ https://t.co/lp8fQ0gLd2
#HemOnc
Missed our Post-ASH 2025 highlights webinars? ๐ป ๐ฉธ Catch up below! ๐
Featuring presentations & discussions on selected abstracts from the 67th ASH Annual Meeting and Exposition ๐บ๐ธ ๐ฆ
Covering:
๐ #AML
๐ Multiple #Myeloma
๐ #MPNs
๐ #MDS
๐ #CLL
๐ #Lymhpoma
+ Panel discussions answering YOUR questions ๐ฌ
Explore the Post-ASH 2025 highlights now ๐ https://t.co/dQPU1CLUqW
Missed our Post-ASH 2025 #MPNs highlights webinar?๐ป ๐ฉธ Catch up below! ๐
Chair: @harrisoncn1 | Moderators: Francesca Palandri and John Mascarenhas
Covering:
๐ Session 1: Advances in the management of PV and ET
๐ Session 2: Latest in MF therapies
๐ Session 3: Novel therapeutic approaches for MPNs and mastocytosis
+ Panel discussion answering YOUR questions ๐ฌ
Explore the #MPN highlights ๐ https://t.co/lp8fQ0gLd2
2026 NCCN guidelines now list ropeginterferon alfa 2b njft (besremiยฎ) as a category 1 preferred option for certain high-risk essential thrombocythemia (ET) patients! While use in ET remains investigational and under FDA review, more options are important for people with #MPNs.
This recently published paper shows that patients with #MPNs experience notable impairments in daily functioning, especially fatigue. The authors highlight that clinicians often underestimate symptom burden, reinforcing the need for routine patientโreported outcomes.
Read more in depth here ๐https://t.co/njzrmLs74I
The biggest #ASH25 takeaways, discussed by global experts ๐ก ๐
Join our Post ASH 2025 Highlights webinar series ๐ป ๐ฉธ
๐๏ธ 22nd Jan - 11th Feb
Covering: #AML (@charliecraddock) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)
Register now to secure your place ๐ https://t.co/dQPU1CLUqW
#PostASH #Hematology #Oncology
First of 2 important #PPI sessions today - great to bring @alex_tonks @NRodriguesLab & @ShuchiChromaBio together with 8 ppl affected by #AML /#MPNs really interesting & insightful discussion incl challenge of involving patients/carers in basic/lab based research @BloodCancer_Res
The biggest #ASH25 takeaways, discussed by global experts ๐ก ๐
Join our Post ASH 2025 Highlights webinar series ๐ป ๐ฉธ
๐๏ธ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)
Register now to secure your place ๐ https://t.co/dQPU1CLUqW
#PostASH #Hematology #Oncology
The biggest #ASH25 takeaways, discussed by global experts ๐ก ๐
Join our Post ASH 2025 Highlights webinar series ๐ป ๐ฉธ
๐๏ธ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)
Register now to secure your place ๐ https://t.co/dQPU1CLUqW
#PostASH #Hematology #Oncology
๐ Congrats to Drs. @mpdrc (@AtriumHealthWFB) and Radek Skoda (@bcmhouston) for receiving the Ernest Beutler Lecture and Prize at #ASH25!
๐ฐ Read more about their roles in advancing the understanding of #MPNs through JAK signaling.
โก๏ธ https://t.co/zG4Rg4UFE4
Most Popular Users
Elon Musk 
@elonmusk
240.8M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111.1M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
87.9M followers
Taylor Swift
@taylorswift13
81.8M followers
Lady Gaga
@ladygaga
73.3M followers
Virat Kohli
@imvkohli
70.3M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64M followers
Neymar Jr
@neymarjr
63.1M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61M followers
X
@x
60.8M followers